PDCD1 and melanoma: In the Checkmate 067 study, the absolute difference in the 6-year PFS and OS rates was greater for ipilimumab/nivolumab than nivolumab monotherapy in patients with BRAFV600-mutant disease (38% and 23%, respectively), whereas a smaller difference was shown in BRAFwt patients (34% and 32%, respectively), underlying that although responses to anti-PD-1 seem to be independent of the BRAF status, patients with BRAFV600-mutant melanoma seem to benefit more from ipilimumab/nivolumab [5].